Table 1 Clinical characteristics and peritoneal cytokine concentrations§ according to peritoneal cancer burdens. (143 patients).
pT3 or less (n = 78) | pT4 (n = 39) | M1c (n = 26) | P | |
|---|---|---|---|---|
Age, years (mean ± SD) | 65.7 ± 12.3 | 68.8 ± 10.7 | 65.4 ± 12.4 | 0.359 |
Gender | 0.243 | |||
Male | 60 (76.9%) | 26 (66.7%) | 16 (61.5%) | |
Female | 18 (23.1%) | 13 (33.3%) | 10 (38.5%) | |
Tumor location | 0.340 | |||
A-colon | 19 (24.4%) | 13 (33.3%) | 9 (34.6%) | |
T-colon | 6 (7.7%) | 5 (12.8%) | 0 (0.0%) | |
D-colon | 5 (6.4%) | 3 (7.7%) | 2 (7.7%) | |
S-colon | 17 (21.8%) | 8 (20.5%) | 10 (38.5%) | |
Upper rectum | 31 (39.7%) | 10 (25.6%) | 5 (19.2%) | |
TNM stage | < 0.001 | |||
I | 12 (15.4%) | 0 (0.0%) | 0 (0.0%) | |
II | 33 (42.3%) | 15 (38.5%) | 0 (0.0%) | |
III | 28 (35.9%) | 15 (38.5%) | 0 (0.0%) | |
IV | 5 (6.4%) | 9 (23.1%) | 26 (100) | |
IL2 (pg/mL) | 4.4 (3.9, 5.2) | 4.6 (4.0, 5.1) | 5.2 (4.5, 6.0) | 0.011 |
IL4 (pg/mL)*,‡ | 1.1 (0.8, 1.9) | 1.9 (0.7, 2.3) | 2.7 (2.4, 3.8) | < 0.001 |
IL5 (pg/mL) | 4.4 (4.1, 5.3) | 3.8 (3.4, 6.4) | 4.8 (4.1, 9.5) | 0.017 |
IL6 (pg/mL)*,‡ | 123.2 (35.7, 418.0) | 260.9 (51.5, 1159.1) | 2,149.0 (731.5, 6,225.0) | < 0.001 |
IL10 (pg/mL)*,‡ | 13.8 (9.1, 19.2) | 18.4 (10.7, 34.9) | 94.1 (30.9, 195.3) | < 0.001 |
IL12 (pg/mL)*,† | 2.2 (2.1, 2.7) | 2.9 (2.8, 3.1) | 3.0 (2.9, 3.1) | < 0.001 |
IL17 (pg/mL) | 4.7 (4.1, 6.1) | 4.4 (4.0, 7.1) | 6.1 (4.5, 6.8) | 0.051 |
IFNG (pg/mL) | 4.9 (4.0, 7.1) | 5.8 (4.5, 8.6) | 6.2 (5.2, 7.3) | 0.041 |
TNF (pg/mL) | 2.3 (2.2, 2.6) | 2.2 (2.1, 2.8) | 2.4 (2.1, 3.1) | 0.245 |
TGFB1 (pg/mL)* | 172.2 (95.3, 259.9) | 231.8 (142.1, 345.8) | 287.5 (201.0, 646.3) | 0.002 |
